Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can we predict growth problems in childhood cancer survivors?

NCT ID NCT07750444

Knowledge-focused Sponsor: Fabiën Belle Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This study looks at how childhood cancer and its treatment affect weight and height from birth into adulthood. Researchers will track body mass index and growth in over 12,000 patients and survivors across Europe. They aim to identify factors that lead to being underweight, overweight, or having stunted growth. The goal is to better understand and potentially improve nutritional care for these patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to better ways to monitor and support healthy growth in childhood cancer survivors, potentially improving their long-term well-being.
What could go wrong
This is an observational study, so it cannot prove cause and effect. The findings may vary across countries and may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 12,150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients diagnosed before age 20 with leukaemia, lymphoma, central nervous system tumours, or malignant solid tumours, in Switzerland, Portugal, or Slovenia.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosed with cancer at age \<20 years * Diagnosed between 2004 and 2026 * Treated in one of the participating cancer centres: 1. Switzerland: patients who visited one of the cancer centres in Switzerland: Aarau, Basel, Bellinzona, Bern, Geneva, Lausanne, Lucerne, St. Gallen, Zurich. 2. Portugal: patients diagnosed between 2012-2026 at the Portuguese paediatric oncology centres Instituto Português de Oncologia do Porto Francisco Gentil - IPO-PORTO or at the Instituto Português de Oncologia Francisco Gentil - IPOLFG. 3. Slovenia: patients diagnosed between 2011-2026 at the paediatric oncology clinic University Medical Center Ljubljana.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Childhood cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

childhood malignant neoplasm neoplasm Obesity Overweight Thinness

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Childhood cancer

Contacts and locations

Locations

  • Centre hospitalier universitaire vaudois (CHUV)

    Lausanne, Lausanne, 1005, Switzerland

  • HOCH Health Ostschweiz Kantonsspital St.Gallen

    Sankt Gallen, Canton of St. Gallen, 9000, Switzerland

  • Hôpitaux Universitaires de Genève (HUG)

    Geneva, Canton of Geneva, 1205, Switzerland

  • Institute of Social and Preventive Medicine (ISPM), Universität Bern

    Bern, Canton of Bern, 3012, Switzerland

  • Kantonsspital Aarau AG

    Aarau, Aarau, 5001, Switzerland

  • Kinderklinik, Inselspital Bern

    Bern, Canton of Bern, 3010, Switzerland

  • Kinderspital Zentralschweiz, Luzern

    Lucerne, Canton of Lucerne, 6004, Switzerland

  • Kinderspital Zürich

    Zurich, Canton of Zurich, 8008, Switzerland

  • Ospedale Regionale di Bellinzona

    Bellinzona, Canton Ticino, 6500, Switzerland

  • Ostschweizer Kinderspital

    Sankt Gallen, Canton of St. Gallen, 9006, Switzerland

  • Universitäts-Kinderspital beider Basel (UKBB)

    Basel, Basel, 4031, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.